The oral direct factor Xa inhibitor, edoxaban, may be as effective as warfarin for the prevention of symptomatic recurrent venous thromboembolism (VTE), with less clinically relevant bleeding, for patients with cancer, a study published in the journal The Lancet Haematology has shown.

Recurrent VTE occurred in 4% of the 378 patients who received edoxaban, compared with 7% of the 393 patients who received warfarin. Edoxaban was not non-inferior to warfarin.

The study demonstrated that 12% of patients who were given edoxaban experienced clinically relevant bleeding, versus 19% of those who received warfarin.